SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after the National Comprehensive Cancer Network updated its clinical guidelines to include ANKTIVA for a broader range of bladder cancer patients, signaling a significant expansion of the drug's eligible treatment population. The community is buzzing over this potential catalyst for increased insurance coverage and revenue, while actively discussing the long-term outlook for the company's immunotherapy platform as it gains momentum in both clinical and international markets.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging following a massive five-year, $27 billion AI infrastructure deal with Meta, which builds on a recent $2 billion equity investment from Nvidia. The community is heavily focused on the company's rapid hyperscaler expansion, debating the implications of this contract for future revenue and whether the stock's valuation is poised for a sustained breakout or a potential pullback.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is currently trading in a tight consolidation range as investors weigh record-breaking revenue and strong AI infrastructure demand against margin compression concerns and lingering sentiment around historical accounting reports. The community is actively debating the company's long-term value, with many hopeful that upcoming industry conferences and strategic NVIDIA ecosystem partnerships will finally catalyze a breakout from the stock's multi-month sideways trend.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending after reporting that the non-HLA-A*02 arm of its Phase III FLAMINGO-01 trial shows a continued reduction in recurrence rates, mirroring promising Phase II results. The community is actively discussing the potential for a major data catalyst following the announcement that the full Steering Committee will co-author upcoming AACR abstracts, with many longs viewing recent price consolidation as a strategic entry point.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is facing significant operational headwinds as a prolonged government shutdown triggers mandatory flight capacity cuts and widespread cancellations, putting pressure on industry profit guidance. Despite these challenges, market sentiment remains cautiously optimistic as investors monitor the impact of rising fuel costs against the backdrop of robust travel demand and resilient corporate booking trends.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is drawing significant investor attention due to a surge in trading volume and speculation regarding a potential short squeeze, fueled by its pivot toward stablecoin settlement and institutional infrastructure. The community is actively discussing recent corporate developments, including share dilution, and is keenly anticipating an upcoming Investor Day that many hope will clarify the company's long-term growth strategy.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Ripple's XRP is trending as traders closely monitor its recent price action and resistance levels, with many community members debating whether the current move is a sustainable breakout or another manipulation trap. The conversation is heavily polarized between long-term holders citing institutional adoption and potential utility, and skeptics who remain wary of market volatility and its historical correlation with broader crypto movements.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending following the announcement of a major robotaxi partnership with Nvidia, aimed at deploying a global fleet of autonomous vehicles across 28 cities by 2028. The community is actively debating the company's long-term valuation and strategic pivot toward becoming a comprehensive mobility platform, with many investors expressing optimism about the scale of these autonomous collaborations.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as investors focus on the recent appointment of Ted Warner as CFO, which the community interprets as a signal of imminent hyperscaler partnerships. While some traders are capitalizing on high volatility and speculative momentum, others are voicing frustration over delayed tenant announcements and potential dilution, maintaining a cautious wait-and-see approach.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in trading volume and investor interest as the market anticipates potential product updates and partnership news at the upcoming OFC conference. Community discussion is heavily focused on the company's progress in scaling manufacturing for AI-driven optical interconnects, with traders debating whether upcoming industry events will provide the long-awaited catalyst for sustained price momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The German drugmaker will transfer select intellectual property to the new entity while retaining a minority stake.</li><li>The new entity will operate independently with its own financial structure, research agenda, and operational framework.</li><li>BioNTech will continue concentrating on its expanding late-stage development portfolio.</li></ul>BioNTech SE (BNTX) on Tuesday revealed plans to launch a separate biotechnology venture dedicated to advancing next-generation messenger RNA technologies, with the initiative to be led by its co-founders Ugur Sahin and Prof. Özlem Türeci, who are set to leave the company to head the new venture.&nbsp;&nbsp;The new entity will operate independently with its own financial structure, research agenda, and operational framework while collaborating with BioNTech in specific areas of development.Following the announcement, BioNTech stock tumbled nearly 17% in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h3>Founders Exit To Lead New mRNA Venture</h3>The Germany-based company intends to transfer certain intellectual property and technology assets tied to mRNA research to the new organization while retaining a minority ownership stake and potential milestone or royalty payments.The forthcoming company will concentrate exclusively on developing emerging mRNA platform technologies with potential medical applications.<h3>BioNTech Keeps Focus On Oncology Pipeline</h3>While the new venture focuses on experimental mRNA innovation, BioNTech will continue concentrating on its expanding late-stage development portfolio. The company expects around 15 Phase 3 clinical trials in oncology to be underway by the end of 2026.&nbsp;“We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients”.-Helmut Jeggle, Chairman, BioNTech Supervisory Board<h2 class="st-heading-2">Q4 Earnings Pressure&nbsp;</h2>BioNTech reported a 23% year-on-year (YoY) decline in fourth-quarter earnings to €907.4 million ($1.05 billion). Loss per share also widened to €1.25 from a loss per share of €0.33 last year.&nbsp;BNTX stock has declined by 3% in the last 12 months.&nbsp;Conversion Rate: €1=$1.16Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/att-250-billion-fiber-5g-network-investment-plan/cZdoY58RIew">AT&amp;T Is Spending $250B On Connectivity In The US – Here’s Where The Money Is Going</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioNTech mRNA-based vaccine manufacturing site in Rwanda | Source: BioNTech

Why Did BNTX Stock Tumble 17% Pre-Market Today? 

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  

Equity

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  


<ul class="summary-bullets"><li>The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.</li><li>Interim analysis of the Phase 2 trial showed 84% of patients on the combo maintained a complete response, compared to 52% on BCG alone at nine months.</li><li>ImmunityBio’s 431% revenue growth in Q4 was largely driven by ANKTIVA sales, the company said.</li></ul>Shares of ImmunityBio (IBRX) reversed pre-market gains to trade 3% lower on Thursday&nbsp;after the company completed enrollment ahead of schedule in its Phase 2 ANKTIVA trial and reported that an FDA-requested interim analysis showed significantly longer complete responses with no major safety concerns.The Phase 2 trial studied ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve non-muscle invasive bladder cancer. The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.The company plans to submit a biologics license application by the fourth quarter of 2026.&nbsp;Last week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">granted</a> conditional marketing approval for Anktiva to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.<h2 class="st-heading-2">ANKTIVA-BCG Combo Significantly Improves Complete Response Duration</h2>An interim analysis requested by the U.S. Food and Drug Administration (FDA) showed that the combination significantly improved the duration of complete response, with no major safety concerns. At nine months, 84% of patients on the combo maintained a complete response, compared with 52% on BCG alone.“We are encouraged by these interim results and await the final unblinding of the completed trial. If approved, ANKTIVA plus BCG could offer a new treatment option earlier in the disease course for patients with NMIBC CIS, building on the therapy’s existing approval in the BCG-unresponsive setting,” said Patrick Soon-Shiong, Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.ANKTIVA continues to power ImmunityBio’s growth, with fourth-quarter net product revenue soaring 431% to $38.3 million, beating Wall Street expectations on strong sales of the drug.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on for <a href="https://stocktwits.com/symbol/IBRX/sentiment">IBRX</a> Stocktwits has remained ‘extremely bullish’ zone for the past six months, while message volumes have been ‘extremely high’.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_b893b9958b.webp" alt="IBRX.jpg">One user said the trial’s outcome is strong enough to justify considering Anktiva + BCG as the “standard of care in BCG-naive NMIBC.”<stembedurl>https://stocktwits.com/Adi121/message/645956934</stembedurl>Another user expects consolidation before the next leg of the rally.<stembedurl>https://stocktwits.com/Texas12/message/645972831</stembedurl>Year-to-date, the stock has shot up 350%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

AI Scare Back in the Market: ETFs That Stayed Steady

AI fears rattled markets as IBM sank and tech slid, but ETFs like OIH, BWET, IDNA and HDGE stayed resilient, gaining even as major indexes fell.

<ul class="summary-bullets"><li>Moderna has submitted a revised approach to streamline approval based on age-specific indications.</li><li>The company proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults 65 and older.</li><li>Last week, the FDA refused to review Moderna’s application for the flu vaccine.</li></ul>Moderna, Inc. (MRNA) said on Wednesday that it is moving forward with regulatory review for its investigational seasonal flu vaccine, mRNA-1010, after responding to a prior Refusal-to-File letter from the U.S. Food and Drug Administration (FDA).&nbsp;The company has submitted a revised approach to streamline approvals based on age-specific indications.<h2 class="st-heading-2">Targeted Approval Strategy</h2>Moderna proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older, along with a post-marketing study to further evaluate safety and efficacy in older populations.The FDA has now accepted the biologics license application (BLA) for review, setting a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 5, 2026.<blockquote>"Pending FDA approval, we look forward to making our flu vaccine available later this year so that America's seniors have access to a new option to protect themselves against flu."-Stéphane Bancel, CEO, Moderna</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> traded over 5% higher on Wednesday morning. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_18_091941_png_316eca4dee.webp" alt="MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global Regulatory Progress</h2>mRNA-1010 has entered regulatory review not only in the U.S. but also in Europe, Canada, and Australia, with additional filings planned for later in 2026. Moderna anticipates the first potential approvals for the vaccine to occur within the year.If approved, mRNA-1010 would be available for U.S. adults aged 50 and above, including those 65 and older, for the 2026/2027 influenza season.&nbsp;Last week, the FDA refused to review Moderna’s application for the flu vaccine and cited the lack of an "adequate and well-controlled" study with a comparator arm that "does not reflect the best-available standard of care."&nbsp;MRNA stock has gained over 28% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/walmart-earnings-can-wmt-stock-sustain-momentum-under-new-ceo/cZR0ZxRR4Hs">Walmart Earnings Ahead: Can WMT Stock Sustain Momentum Under New CEO?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

<ul class="summary-bullets"><li>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following subcutaneous administration.</li><li>Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients.</li><li>The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.</li></ul>Alvotech (ALVO) shares were up nearly 10% in Thursday’s pre-market trade after the company announced positive top-line results from its pharmacokinetic study.The company stated that the study showed that AVT80, its biosimilar candidate to Entyvio, met all its primary endpoints.“We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio, allowing us to proceed towards regulatory submissions,” said Alvotech COO Joseph McClellan.<h2 class="st-heading-2">Details Of The Pharmacokinetics Study</h2>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following a single 108 mg/0.68 mL subcutaneous (SC) injection.Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients. The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.Alvotech also stated that it is currently developing AVT16, a proposed biosimilar to Entyvio for intravenous administration, while AVT80 is designed for subcutaneous administration.The Pharmacokinetic study for AVT80 is crucial to demonstrating clinical similarity between AVT16 and AVT80, the company added.<h2 class="st-heading-2">What Does Alvotech Do?</h2>Alvotech is a Reykjavik, Iceland-based biotechnology company that is focused exclusively on developing biosimilar medicines.The company has two biosimilars, Humira and Stelara, already approved and marketed in multiple markets around the world. Alvotech has partnered with multiple companies globally, including Teva Pharmaceuticals, Cipla, Dr. Reddy’s, and Lotus Pharmaceuticals, among others.&nbsp;<h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ALVO">Alvotech</a> was in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels. The ALVO ticker was the fourth most trending ticker on the platform at the time of writing.One bullish user called the top-line results “huge news” for Alvotech.<stembedurl>https://stocktwits.com/NewsTrader_perform4nce/message/644068023</stembedurl><a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 1% year-to-date and 59% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-excellent-call-with-china-xi-jinping-trip-in-april/cZbj5hCR4Z6">Trump Announces He Had An ‘Excellent’ Call With Chinese President Xi Jinping, Says He Will Travel In April To China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alvotech logo is seen displayed on a smartphone screen

Why Is ALVO Stock Rising Pre-Market Today?

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

Current Price	$29.46
Prev Close	$28.78
Open	$29.33
Dividend Yield	N/A
50-Day Moving Average	$29.06
Beta	N/A
Avg. Volume	38,430.58
PE Ratio	N/A

52-Week High	$31.39
52-Week Low	$17.26
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IDNA
iShares Genomics Immunology and Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IDNA News

IDNAiShares Genomics Immunology and Healthcare ETF